

Curriculum Vitae

Mark Richard Thursz

January 2023

BASCIS

Nationality British
GMC Number 3137956
Address Toads on the Green, Potten End, Berkhamsted, HP4 2QQ
Telephone 0207 886 1903
PA Dawn Campbell 0203 312 6454
Email m.thursz@imperial.ac.uk

EDUCATION

1981 – 1986 King's College School of Medicine & Dentistry, London

QUALIFICATIONS

June 1986 MBBS, University of London
June 1989 MRCP, University of London
March 1997 MD, University of London
July 2004 FRCP, University of London

CURRENT & PREVIOUS APPOINTMENTS

01-08-19 – present Head of Department of Metabolism, Digestion & Reproduction
01-08-18 – 01-08-19 Interim Head Department of Surgery & Cancer
01.10.17 – present Director Imperial Biomedical Research Centre
01.10.17 – present Trust Research Director Imperial College Healthcare NHS Trust
01.05-17 – 31.03.18 Specialty Lead Hepatology. NW London CRN
01.05.16 – 28.02.18 Chair Faculty of Medicine Health Safety & Environment Committee
01.08.15 – present Head of Division of Digestive Diseases, Imperial College London
01.09.14 – 28.02.18 Campus Director, St Mary's Hospital Campus
01.04.11 – present Head of Section Gastroenterology & Hepatology, Imperial College London
01.04.10 – present Clinical Lead Hepatology, Imperial College Healthcare
01.05.11 – 30.04.13 Secretary General European Association for Study of the Liver
01.05.09 – 30.04.11 Vice-Secretary European Association for Study of the Liver
01.04.07 – 31.03.17 BRC Theme Lead Gastroenterology & Hepatology
07.07.06 – present Professor of Hepatology, Imperial College London
01.10.02 – 30.09.05 Secretary British Association for Study of the Liver
01.04.99 – 30.03.01 Clinical Lead in Gastroenterology, St Mary's Hospital. Paddington
01.05.97 – 07.07.06 Senior Lecturer & Reader in Medicine, Imperial College London
01.05.97 – present Honorary Consultant Gastroenterology & Hepatology, Imperial Healthcare NHS Trust
01.05.95 – 30.04.97 Lecturer, Department of Medicine, Imperial College School of Medicine

Advisory & Consultancy Roles

01.07.21 – present Chair BRC Directors Forum / Member NIHR Strategy Board
01.06.18 – 31.05.22 NIHR-EME Board Member
01.12.14 – 31.01.18 Hepatitis C Coalition – Chair
01.09.14 – present St Mary's Development Trust Board Member
01.02.15 – present Imperial College Healthcare Charity Grants Committee
01.03-15 – 28.02.16 Department of Health/NHS-England/Public Health England Partnership Group on Hepatitis C
WHO Guidelines Development Group: Hepatitis B

Awards and Honours

2004 Linacre Lectureship
2018 British Society for Gastroenterology Sheila Sherlock Medal
2019 NIHR Senior Investigator
2017 Visiting Professor, University of Toronto
2013 Visiting Professor, University of Padua

GRANTS & FELLOWSHIPS

Infrastructure Awards

- NIHR Capital Equipment Award 2023 £4.7M
- NIHR Imperial Biomedical Research Centre 2022 – 27 £95.3M
- NIHR Capital Funding for Antimicrobial resistance 2018 £2.7M

Personal Funding

- MRC Experimental Medicine: PD1 Inhibition in Liver Failure £1M 2022 – 2024
- MRC Stratified Medicine: Minimising Mortality from Alcoholic Hepatitis 2018 – 2023. £5.6M
- NIH. GenomeALC \$3.2M Co-Investigator 2016 - 18
- Novartis Pharmaceuticals. Inhibition of IL-1 Signalling in Alcoholic Hepatitis (ISAIHA) trial. £1.2M 2017-19.
- National Institute for Medical Research-EME Trial grant. Nucleoside Analogue Withdrawal in HBeAg negative patients with chronic hepatitis B (NUC-B). £2M 2016-2021.
- MRC Clinical Research Training Fellowship Dr Stephen Atkinson: “Genomic and metabolomic markers in alcoholic hepatitis” 2015 - 2018
- MRC Clinical Research Fellowship Dr Shevanthi Nayagam: “Mathematical models to predict the outcome of public health interventions to control hepatitis B virus”. 2013-2016
- Wellcome Trust Clinical Research Fellowship Dr Nikhil Vergis: “Monocyte dysfunction in alcoholic hepatitis” 2012 – 2015
- EC FP7 Grant: Participant “Dengue Framework for Resisting Epidemics in Europe (Denfree)”. €210,000 of €3M Nov 2011 – Oct 2016
- EC FP7 Grant: Coordinator “Prevention of Liver Fibrosis and Cancer in Africa (Prolifica)”. €3M March 2011 – Feb 2016.
- EC FP7 Grant: Participant “Host and viral factors in acute hepatitis C (HepAcute)”. €300,000 of €3M March 2010 – Feb 2013.
- MRC Clinical Research Training Fellowship – Dr Lucia Possamai “Genetic and environmental determinants of paracetamol toxicity.” Oct 2009 – Sept 2012.
- NHS Health Technology Assessment – Clinical Trials Grant: “Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH)”. £2.5M. July 2009 – June 2013
- MRC Experimental Medicine: “Warfarin Anticoagulation for Liver Fibrosis in patients Transplanted for Hepatitis C Virus infection (WAFT-C)”. £720,000 July 2008 – June 2013.

Previous Grants and Fellowships

- Astellas Pharmaceuticals. Warfarin Anticoagulation for Liver Fibrosis in patients Transplanted for Hepatitis C Virus infection (WAFT-C). Pilot £171,000 April 2007 – March 2010.
- MRC Programme Grant. Mouse Models of Liver Disease. £1.7M Jan 2007 – 2011. (HC Thomas, R Cox, SD Brown, Q Anstee)
- Wellcome Trust Clinical Training Fellowship – Dr Helen Matthews. Oxidative defense in non-alcoholic fatty liver disease
- REFLUX – NHS Health Technology Assessment Trials. Comparison of Surgical and Medical Treatment of GORD. £0.9M, May 2002, 3 years. (Multicentre).
- St Mary’s Hospital Trustees. Microarray analysis of a Mouse Model of NASH. £8,000, October 2004, 1 year. (With Dr Q Anstee)
- Intercell / ICON Trial. Therapeutic Vaccination for HCV Infection. £12,000, May 2003 18 months.
- MRC Clinical Training Fellowship – Dr Quentin Anstee. Development of a Mouse Model of NASH. £150,000 Oct 2004 – Sept 2006
- RioTech Pharmaceuticals Ltd. Development of drug screening assays for PDE12. £65,000. March 2004, 6 months
- European Commission Framework 6. “European Vigilance Network for the Management of Antiviral Drug Resistance” 95,000 Euros April 2004 5 years. (Multicentre)
- MRC Clinical Training Fellowship – Dr Mark Wright. Genetic susceptibility to liver fibrosis in hepatitis C infection. May 2001. £120,000 3 years
- MRC Career Establishment Grant. “Genetic Susceptibility in *H. pylori* Infection” £720,000 – 5 years 1/2/01 – 31/1/06

- Department of Health. “Natural history of transfusion acquired hepatitis C virus infection.” £300,000. 1/5/97 - 3 years. (Multicentre led from ICSM with Prof H Thomas)
- GlaxoWellcome. “Determining the burden of chronic hepatitis B and C virus infection.” £94,100. 1/12/96 - 1 year
- British Digestive Foundation Fellowship (Dr AE Griffiths). Genetic Susceptibility to H. Pylori infection. £60,000. 1/10/96 - 2 years
- Roche Research. £2.6 million to Prof HC Thomas, Dr MR Thursz, Prof AVS Hill and Prof JI Bell (of the Wellcome Trust Centre for Human Genetics, Oxford) for research on genetic susceptibility in hepatitis B and C virus infections. 1/1/97 - 5 years
- European Commission DG(XII) Biomed 2 Programme. €300,000 for research on the immunogenetics of hepatitis B virus infection - coordinated from ICSM at St Mary’s. 1/5/96 - 3 years. (Multicentre led from ICSM with Prof H Thomas)
- European Commission DG(V) Public Health. €1,200,000 for epidemiological and immunogenetic research on hepatitis C virus infection in 8 European Centres - coordinated from ICSM at St Mary’s. 1/10/95 - 2 years (Multicentre led from ICSM with Prof H Thomas)

JOURNALS

Editorial Board Journal of Hepatology 2019 – 2022
 Co-Editor - Journal of Viral Hepatitis 2013 – 2017
 Editorial Board – Hepatology 2009 – 2013
 Editorial Board – Annals of Gastroenterology 2011 – present

GRANT GIVING BODIES

Committee member NIHR-EME 2017 - 2021
 Committee member Imperial College Healthcare Charity 2017 – present
 Committee Member Guts UK 2013-16

CURRENT RESEARCH

Alcoholic Hepatitis

Funding: MRC Stratified Medicine Award. Novartis

Collaborators: Multiple

Completion of the Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial stimulated substantial interest in the development of novel therapeutics for this condition. We completed the Inhibition of IL-1 Signalling in Alcoholic Hepatitis (ISAIAH) study in November 2021 funded by Novartis. The Minimising Mortality in Alcoholic Hepatitis (MIMAH) application received an MRC Stratified Medicine award to develop biomarkers to guide the clinical management of this condition using metabonomic, genomic and proteomic approaches

NUC-B Trial

Funding: NIHR EME

Collaborators: Multiple

I am chief investigator on a trial designed to evaluate strategies to increase the chance of HBsAg loss in patients with HBeAg negative chronic hepatitis B virus infection. The trial will compare simple nucleoside analogue withdrawal against nucleoside withdrawal coupled with a short course of interferon. Patients who have been on nucleoside analogue therapy for at least 3 years are currently being followed up for 3 years after treatment withdrawal.

PROLIFICA

Funding: EC FP7, Gilead Foundation, MRC NIRG (Maud Lemoine)

Collaborators: Dr Maud Lemoine. Inserm U1052, Lyon, IARC, Xepatgen AG, Ministry of Health Gambia, MRC Labs Gambia, University Cheikh Anta Diop Senegal, Jos University Teach Hospital Nigeria.

I was coordinator of this European Commission FP7 funded programme on hepatitis B virus infection and hepatocellular carcinoma (HCC) in West Africa. There are two research platforms: firstly, a case-control study designed to generate samples from 700 HCC cases and 1400 (700 HBV infected and 700 healthy) controls which will be used to identify genomic, proteomic and metabonomic markers for liver cancer in this population.

In the second platform we screened over 13,000 adults in the general population with a point-of-care test for HBV. Linkage to care and eligibility for treatment were assessed allowing us to assess the feasibility, clinical effectiveness and cost-effectiveness of a screen and treat strategy for HBV in West Africa. We are now undertaking follow up studies of both treated and untreated patients with chronic HBV in order to re-assess treatment eligibility criteria.

Monocytes & Macrophages in Liver Failure

Funding: MRC Experimental Medicine, Medical Research Foundation, Rosetrees Foundation and NIHR Lectureship

Collaborators: Prof David Adams & Prof Lalor (Birmingham) Prof Wendon (King's College Hospital).

We have identified a number of phenotypic abnormalities in both peripheral monocytes and hepatic macrophages in acute liver failure, acute-on-chronic liver failure and alcoholic hepatitis. These abnormalities may explain the high level of susceptibility to infection in these groups of patients and also reveals a role for these cells in liver regeneration. In alcoholic hepatitis we identified a defect in monocyte oxidative burst which increases risk of infection 12-fold but may be reversible with N-acetylcysteine. Most recently we have identified a phagocytic defect in Kupffer cells and monocytes which allows system dissemination of invasive microbes. As this defect appears to be reversible with PD-1 inhibition we are currently exploring the clinical utility of Nivolumab treatment in acute liver failure and acute decompensation.

MANAGEMENT AND LEADERSHIP

Trust Director of Research & Biomedical Research Centre Director

Responsible for developing, agreeing and implementing action plans for the BRC and Trust Research. Ensuring high levels of research governance, financial transparency and promoting innovation. Facilitation of research translation locally, nationally and internationally. Develop the reputation of the BRC and trust research as a leading organisation for multi-disciplinary translational healthcare research and patient care, both nationally and internationally. Expand the Trust research portfolio for commercial and non-commercial studies. Engage with the North West London NIHR CRN and ICS. I led the 2022-27 BRC application resulting in an award of £95.3M

Head of Department of Metabolism Digestion & Reproduction

Following restructuring of the Faculty of Medicine at Imperial in 2019 I was invited to set up and run the Department of Metabolism, Digestion and Reproduction. United by a common interest in metabolism, microbiome and endocrinology the Department hosts 200 academic staff across a number of disciplines and specialties. With an active People & Culture committee we have already secured an Athena Swan Silver award which realistically reflects the respectful environment of the Department.

Co-Director Imperial – CNRS International Research Project Metabo-Lic

I have established a joint programme with the University of Lille on human integrative metabolism which will facilitate cooperative research projects and scientific exchanges between the Department of Metabolism Digestion & Reproduction at Imperial and UMR8199 at the University of Lille (led by Prof Marc-Emmanuel Dumas)

Clinical Academic Training

I co-ordinated a successful bid for Walport Integrated Academic Training posts and have run the scheme for Gastroenterology and Hepatology within Imperial Healthcare for the last 11 years. We currently have 2 clinical lecturers and 3 clinical fellows on the scheme. The majority of previous fellows have gone on to achieve research training fellowships from Wellcome or MRC. Two previous trainees have progressed to chairs in other UK institutions.

NorthWest London is the most competitive Gastroenterology training scheme in the UK. The clinical and academic training opportunities attract the highest calibre of ST3 applicants. As a result >75% of trainees achieve an MD/PhD prior to CCT.

POSTGRADUATE TRAINEES

Name	Funding	Degree /Duration	Destination
Uga Dumpis	Industry 1997	PhD 3 years	Professor of Infectious Disease, Riga
Umakant Dave	BSG CORE 1998	MD 2 years	NHS Consultant Swansea
Wafa Khamri	Algerian Government 2001	PhD 3 years	Post-doc Imperial
Mark Wright	MRC CRTF 2002	PhD 3 years	NHS consultant / Honorary Snr Lecturer Southampton
Amy Anderson	MRC Project 2002	PhD 3 years	Lecturer Newcastle
Leland Yee	Industry 2003	PhD 3 years	Pharmaceutical Industry USA
Quentin Anstee	MRC CRTF 2005	PhD 3 years	Prof of Hepatology, Newcastle
Rhiannon Lowe	Industry 2007	PhD 5 years	Senior lab manager GSK
Helen Matthews	Wellcome CRTF 2008	Not written up	NHS Consultant London
Adam Levene	NIHR ACF 2009	MD 2 years	NHS Consultant Histopathology, London
Ameet Dhar	MRC Exp Medicine 2009	PhD 3 years	Consultant and Hon Snr Lecturer Imperial College
Yusuke Shimkawa	Japan Research Council	PhD 4 years	Lecturer, Institut Pasteur, Paris
Lucia Possamai	MRC CRTF 2009	PhD 3 years	Lecturer Imperial College
Shevanthi Nayagam	MRC CRTF 2012	PhD 3 years	Lecturer Imperial College
Nikhil Vergis	Wellcome CRTF	PhD 3 years	Senior Lecturer Hepatology
Nowlan Selvapatt	Imperial College Healthcare	PhD 3 years	Consultant Hepatologist
Torben Kimhofer	Stratograd Studentship	PhD 3 years	Post-doctoral Fellowship Imperial
Gemma Petts	Pathological Society Fellowship	PhD 3 years	Returned to clinical training
Stephen Atkinson	MRC CRTF 2014	PhD 4 years	Senior Lecturer Imperial
Benjamin Mullish	MRC Clinical Fellow	PhD 3 years	Clinical Lecturer Imperial College
Gibril Ndow	Wellcome ISSF Fellow	PhD	Ongoing
James Maurice	St Stephens AIDS Trust	PhD	Returned to clinical training
Naveenta Kumar	Wellcome Trust	PhD	Consultant at Royal Free
Alexandra Cateson	Stratograd Studentship 2017	PhD	Withdrew due to ill health
Rooshi Nathwani	Industry Sponsor 2017	PhD	Returned to clinical training
Arjun Singanayagam	Wellcome CRTF	PhD	Senior Lectureship
Sujit Mukerjee	MRC CRTF 2015	PhD	Submitted
Zameer Mohammed	Teaching Fellowship	PhD	Returned to clinical training
Siddhartha Oke	St Marks Fellowship	PhD	Returned to clinical training
Roberta Forlano	EASL Fellowship 2018	PhD	Completed
Kate Gallagher	Stratograd Studentship. 2018	PhD	Completed
Michael Hewitt	Programme grant	PhD	Submitted
Catherine Gudd	Marsden Fellowship	PhD	ICRF
Charlotte Hateley	Wellcome Trust CRTF	PhD	Ongoing
Nadeen Haboub	Stratograd Studentship 2019	PhD	Ongoing
Dan Wang	Guangzhou Elite Scholarship	PhD	Ongoing
Charlotte Skinner	Teaching Fellowship	MD	Ongoing
Luke Tyson	Teaching Fellowship	PhD	Ongoing
Paul Middleton	Chain-Florey Scheme	PhD	Ongoing

PUBLICATIONS

1. Khan RS, Lalor PF, Thursz M, Newsome P. The role of neutrophils in alcohol-related hepatitis. *J Hepatol.* 2023 Jun 6:S0168-8278(23)00346-X. doi:10.1016/j.jhep.2023.05.017. Epub ahead of print. PMID: 37290590.
2. Nayagam S, de Villiers MJ, Shimakawa Y, Lemoine M, Thursz MR, Walsh N, Hallett TB. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study. *Lancet Gastroenterol Hepatol.* 2023 Jul;8(7):635-645. doi: 10.1016/S2468 1253(23)00074-2. Epub 2023 May 5. PMID: 37150181.
3. Arab JP, Addolorato G, Mathurin P, Thursz MR. Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder. *Clin Gastroenterol Hepatol.* 2023 Jul;21(8):2124-2134. doi: 10.1016/j.cgh.2023.02.017. Epub 2023 Feb 27. PMID: 36858144.
4. Jambulingam N, Forlano R, Preston B, Mullish BH, Portone G, Baheer Y, Yee M, Goldin RD, Thursz MR, Manousou P. Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci.* 2023 Feb 10;24(4):3563. doi: 10.3390/ijms24043563. PMID: 36834973; PMCID: PMC9961068
5. Schmit N, Nayagam S, Lemoine M, Ndow G, Shimakawa Y, **Thursz** MR, Hallett TB. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia. *J Glob Health.* 2023 Jan 20;13:04004. doi: 10.7189/jogh.13.04004. PMID: 36655869.
6. Vincent JP, Ndow G, Ogawa S, Ceesay A, Njie R, Sanneh B, Baldeh I, D'Alessandro U, Mendy M, **Thursz** M, Chemin I, Tanaka Y, Lemoine M, Shimakawa Y. Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa. *J Glob Health.* 2022 Nov 12;12:04076. doi: 10.7189/jogh.12.04076. PMID: 36370422; PMCID: PMC9653177
7. Whitfield JB, Seth D, Morgan TR; GenomALC Consortium. All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank. *Alcohol Clin Exp Res.* 2022 Dec;46(12):2245-2257. doi: 10.1111/acer.14968. Epub 2022 Nov 19. PMID: 36317527
8. Sow A, Lemoine M, Toure PS, Diop M, Lo G, De Veiga J, Pape OT, Seck K, Ndow G, Bojang L, Kane A, Oudiane M, Howell J, Nayagam S, Moutchia J, Chemin I, Mendy M, Toure-Kane C, **Thursz** M, Ka M, Shimakawa Y, Mboup S. HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme. *JHEP Rep.* 2022 Jul;4(10):100533. doi: 10.1016/j.jhepr.2022.100533. PMID: 36052221; PMCID: PMC9424572
9. Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y; PROLIFICA/HBcrAg-RDT Study Group. Rapid Point-of-Care Test for Hepatitis B Core-Related Antigen to Diagnose High Viral Load in Resource-Limited Settings. *Clin Gastroenterol Hepatol.* 2022 Jun 11:S1542-3565(22)00554-7. doi:10.1016/j.cgh.2022.05.026. Epub ahead of print. PMID: 35697265

10. Staudacher JJ, Bauer J, Atkinson SR, **Thursz** M, Lang S, Schnabl B, Wiley MB, Carr R, Jung B. Systemic Activin Is Elevated in Patients With Severe Alcoholic Hepatitis. *Gastro Hep Adv.* 2022;1(2):147-149. doi: 10.1016/j.gastha.2021.12.004. Epub 2022 Feb 7. PMID: 35602917; PMCID: PMC9119346
11. Szabo G, **Thursz** M, Shah VH. Therapeutic advances in alcohol-associated hepatitis. *J Hepatol.* 2022 Jun;76(6):1279-1290. doi: 10.1016/j.jhep.2022.03.025.PMID: 35589250
12. Khamri W, Gudd C, Liu T, Nathwani R, Krasniqi M, Azam S, Barbera T, Trovato FM, Possamai L, Triantafyllou E, Seoane RC, Lebosse F, Singanayagam A, Kumar N, Bernsmeier C, Mukherjee S, McPhail M, Weston CJ, Antoniadis CG, **Thursz** MR. Suppressor CD4+ T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis. *Gut.* 2022 Jun;71(6):1192-1202. doi: 10.1136/gutjnl-2021-324071. Epub 2021 Aug 3. PMID: 34344786
13. U MRA, Shen EY, Cartlidge C, Alkhatib A, **Thursz** MR, Waked I, Gomaa AI, Holmes E, Sharma R, Taylor-Robinson SD. Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2022 May 11:ceb.0687.2021. doi: 10.1158/1055-9965.EPI-21-0687. Epub ahead of print. PMID: 35545293
14. Atkinson SR, Aly M, Remih K, Tyson LD, Guldiken N, Goldin R, Quaglia A, **Thursz** M, Strnad P. Serum keratin 19 (CYFRA21-1) is a prognostic biomarker in severe alcoholic hepatitis. *Liver Int.* 2022 May;42(5):1049-1057. doi: 10.1111/liv.15218. Epub 2022 Mar 11. PMID: 35220651
15. Lucey MR, **Thursz** MR. We need a new approach to clinical trials in alcohol-associated hepatitis: Is there a lesson in RECOVERY? *Hepatology.* 2022 Apr 13. doi: 10.1002/hep.32523. Epub ahead of print. PMID: 35416316
16. Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, McClain C, Mellinger J, Szabo G, Terrault N, **Thursz** M, Winder GS, Kim WR, Shah VH. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. *Hepatology.* 2022 Apr;75(4):1026-1037. doi: 10.1002/hep.32143. Epub 2021 Nov 27. PMID: 34496071
17. Kaura A, Hartley A, Panoulas V, Glampson B, Shah ASV, Davies J, Mulla A, Woods K, Omigie J, Shah AD, **Thursz** MR, Elliott P, Hemmingway H, Williams B, Asselbergs FW, O'Sullivan M, Lord GM, Trickey A, Sterne JA, Haskard DO, Melikian N, Francis DP, Koenig W, Shah AM, Kharbanda R, Perera D, Patel RS, Channon KM, Mayet J, Khamis R. Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. *PLoS Med.* 2022 Feb 22;19(2):e1003911. doi: 10.1371/journal.pmed.1003911. PMID: 35192610; PMCID: PMC8863282
18. Morales-Arráez D, Ventura-Cots M, Altamirano J, Abrales JG, Cruz-Lemini M, **Thursz** MR, Atkinson SR, Sarin SK, Kim W, Chavez-Araujo R, Higuera-de la Tijera MF, Singal AK, Shah VH, Kamath PS, Duarte-Rojo A, Charles EA, Vargas V, Jager M, Rautou PE, Rincon D, Zamarripa F, Restrepo-Gutiérrez JC, Torre A, Lucey MR, Arab JP, Mathurin P, Louvet A, García-Tsao G, González JA, Verna EC, Brown RS Jr, Argemi J, Fernández-Carillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term

Mortality in Alcohol-Associated Hepatitis: A Global Study. *Am J Gastroenterol*. 2022 Feb 1;117(2):301-310. doi: 10.14309/ajg.0000000000001596. PMID: 34962498.

19. Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, **Thursz** MR, Trépo E, Morgan TR, Seth D; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. *J Hepatol*. 2022 Feb;76(2):275-282. doi: 10.1016/j.jhep.2021.10.005. Epub 2021 Oct 14. PMID: 34656649; PMCID: PMC8803006.
20. Forlano R, Mullish BH, Roberts LA, **Thursz** MR, Manousou P. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non- Alcoholic Fatty Liver Disease. *Int J Mol Sci*. 2022 Jan 8;23(2):662. doi: 10.3390/ijms23020662. PMID: 35054847; PMCID: PMC8775587.
21. Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, **Thursz** MR, Dhar A. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. *Frontline Gastroenterol*. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. PMID: 34970431; PMCID: PMC8666853.
22. Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, **Thursz** MR, Brown AS, Hellard M, Lemoine M. Cost effectiveness of simplified HCV screening-and- treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. *Int J Drug Policy*. 2022 Jan;99:103458. doi: 10.1016/j.drugpo.2021.103458. Epub 2021 Oct 6. PMID: 34624732.
23. Forlano R, Mullish BH, Dhar A, Goldin RD, **Thursz** M, Manousou P. Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter? *World J Hepatol*. 2021 Dec 27;13(12):2104-2112. doi: 10.4254/wjh.v13.i12.2104. PMID: 35070011; PMCID: PMC8727198.
24. Perez-Guzman PN, Daunt A, Mukherjee S, Crook P, Forlano R, Kont MD, Løchen A, Vollmer M, Middleton P, Judge R, Harlow C, Soubieries A, Cooke G, White PJ, Hallett TB, Aylin P, Ferguson N, Hauck K, **Thursz** MR, Nayagam S. Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. *Clin Infect Dis*. 2021 Dec 6;73(11):e4047-e4057. doi: 10.1093/cid/ciaa1091. PMID: 32766823; PMCID: PMC7454410.
25. Vergis N, Patel V, Bogdanowicz K, Czyzewska-Khan J, Fiorentino F, Day E, Cross M, Foster N, Lord E, Goldin R, Forrest E, **Thursz** M. IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis. *Trials*. 2021 Nov 11;22(1):792. doi: 10.1186/s13063-021-05719-2. PMID: 34763711; PMCID: PMC8581959.

26. Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, McClain C, Mellinger J, Szabo G, Terrault N, **Thursz M**, Winder GS, Kim WR, Shah VH. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. *Hepatology*. 2021 Sep 8. doi: 10.1002/hep.32143. Epub ahead of print. PMID: 34496071.
27. Innes AJ, Mullish BH, Ghani R, Szydlo RM, Apperley JF, Olavarria E, Palanicawandar R, Kanfer EJ, Milojkovic D, McDonald JAK, Brannigan ET, **Thursz MR**, Williams HRT, Davies FJ, Marchesi JR, Pavlů J. Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. *Front Cell Infect Microbiol*. 2021 Aug 27;11:684659. doi: 10.3389/fcimb.2021.684659. PMID: 34513724; PMCID: PMC8430254.
28. Lett AM, Lim A, Skinner C, Maurice J, Vergis N, Darzi A, Goldin R, **Thursz M**, Thompson AJ. Rapid, non-invasive measurement of gastric emptying rate using transcutaneous fluorescence spectroscopy. *Biomed Opt Express*. 2021 Jun 21;12(7):4249-4264. doi: 10.1364/BOE.424252. PMID: 34457412; PMCID: PMC8367270.
29. Khamri W, Gudd C, Liu T, Nathwani R, Krasniqi M, Azam S, Barbera T, Trovato, FM, Possamai L, Triantafyllou E, Seoane RC, Lebosse F, Singanayagam A, Kumar N, Bernsmeier C, Mukherjee S, McPhail M, Weston CJ, Antoniadis CG, **Thursz MR**. Suppressor CD4+ T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis. *Gut*. 2021 Aug 3;gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071. Epub ahead of print. PMID: 34344786.
30. Forlano R, Harlow C, Mullish BH, **Thursz MR**, Manousou P, Yee M. Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. *Int J Eat Disord*. 2021 Jul 17. doi: 10.1002/eat.23584. Epub ahead of print. PMID: 34272900.
31. Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, **Thursz M**, Chemin I, Lemoine M. Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. *J Infect Dis*. 2021 Jun 23;jiab327. doi: 10.1093/infdis/jiab327. Epub ahead of print. PMID: 34160616.
32. Gustot T, Stadlbauer V, Laleman W, Alessandria C, **Thursz M**. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. *J Hepatol*. 2021 Jul;75 Suppl 1:S36-S48. doi: 10.1016/j.jhep.2020.12.005. PMID: 34039491.
33. Pazoki R, Vujkovic M, Elliott J, Evangelou E, Gill D, Ghanbari M, van der Most PJ, Pinto RC, Wielscher M, Farlik M, Zuber V, de Knecht RJ, Snieder H, Uitterlinden AG; Lifelines Cohort Study, Lynch JA, Jiang X, Said S, Kaplan DE, Lee KM, Serper M, Carr RM, Tsao PS, Atkinson SR, Dehghan A, Tzoulaki I, Ikram MA, Herzig KH, Järvelin MR, Alizadeh BZ, O'Donnell CJ, Saleheen D, Voight BF, Chang KM, **Thursz MR**, Elliott P; VA Million Veteran Program. Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. *Nat Commun*. 2021 May 10;12(1):2579. doi: 10.1038/s41467-021-22338-2. PMID: 33972514; PMCID: PMC8110798.

34. Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, **Thursz** M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N. Multi- arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z. PMID: 33845867; PMCID: PMC8039797.
35. Post G, Howell J, Sow A, Ndow G, Chemin I, Lo G, Cessay A, Cohen D, Njie R, Toure S, Diop M, Sombie R, Nana J, Leroy V, Lacombe K, Bojang L, Tacke F, Toure- Kane C, Ka M, Mendy M, Mboup S, **Thursz** M, Shimakawa Y, Ingiliz P, Lemoine M. Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. *J Viral Hepat*. 2021 Jul;28(7):1003-1010. doi: 10.1111/jvh.13499. Epub 2021 May 26. PMID: 33749097.
36. Hui Z, Nayagam S, Chan P, Fuzhen W, **Thursz** M, Zundong Y, Ning M, Xiaojin S, Cui F, Guomin Z, Hallett TB. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. *Bull World Health Organ*. 2021 Jan 1;99(1):10-18. doi: 10.2471/BLT.19.248146. Epub 2020 Oct 28. PMID: 33658732; PMCID: PMC7924890.
37. Gudd CL, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, Kumar N, Mukherjee S, Dhar A, Woollard KJ, Yone Y, Pinato DJ, **Thursz** MR, Goldin RD, Gore ME, Larkin J, Khamri W, Antoniadis CG, Turajlic S, Possamai LA. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. *J Hepatol*. 2021 Feb 22:S0168-8278(21)00108-2. doi: 10.1016/j.jhep.2021.02.008. Epub ahead of print
38. Guldiken N, Argemi J, Gurbuz B, Atkinson SR, Oliverius M, Fila P, Hamesch K, Bruns T, Cabezas J, Lozano JJ, Mann J, Cao S, Mathurin P, Shah VH, Trautwein C, **Thursz** MR, Bataller R, Strnad P. Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. *BMC Med*. 2021 Feb 17;19(1):39. doi: 10.1186/s12916-021-01917-6. PMID: 33593348; PMCID: PMC7887823.
39. Middleton P, Perez-Guzman PN, Cheng A, Kumar N, Kont MD, Daunt A, Mukherjee S, Cooke G, Hallett TB, Hauck K, White PJ, **Thursz** MR, Nayagam S. Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study. *Sci Rep*. 2021 Jan 28;11(1):2455. doi: 10.1038/s41598-021-81930-0. PMID: 33510247; PMCID: PMC7844285.
40. Heffernan A, Ma Y, Nayagam S, Chan P, Chen Z, Cooke GS, Guo Y, Liu C, **Thursz** M, Zhang W, Zhang X, Zhang X, Jia M, Hallett TB. Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. *PLoS One*. 2021 Jan 13;16(1):e0245288. doi: 10.1371/journal.pone.0245288. PMID: 33439903; PMCID: PMC7806158.
41. Schmit N, Nayagam S, **Thursz** MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. *Int J Epidemiol*. 2020 Dec 27:dya253. doi: 10.1093/ije/dyaa253. Epub ahead of print. PMID: 33367672.

42. Forrest E, Petts G, Austin A, Lloyd K, Wright M, Vergis N, Atkinson S, Masson S, Patch D, Quaglia A, **Thursz** M, Goldin R. The diagnostic and prognostic significance of liver histology in alcoholic hepatitis. *Aliment Pharmacol Ther.* 2021 Feb;53(3):426-431. doi: 10.1111/apt.16157. Epub 2020 Dec 16. PMID: 33326633.
43. Triantafyllou E, Gudd CL, Mawhin MA, Husbyn HC, Trovato FM, Siggins MK, O'Connor T, Kudo H, Mukherjee SK, Wendon JA, Bernsmeier C, Goldin RD, Botto M, Khamri W, McPhail MJ, Possamai LA, Woollard KJ, Antoniadou CG, **Thursz** MR. PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. *J Clin Invest.* 2021 Feb 15;131(4):e140196. doi: 10.1172/JCI140196. PMID: 33320839; PMCID: PMC7880414.
44. Atkinson SR, Grove JI, Liebig S, Astbury S, Vergis N, Goldin R, Quaglia A, Bantel H, Guha IN, **Thursz** MR, Newcombe P, Strnad P, Aithal GP. In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers. *Am J Gastroenterol.* 2020 Nov;115(11):1857-1868. doi: 10.14309/ajg.0000000000000912. PMID: 33156105.
45. Skinner C, Thompson AJ, **Thursz** MR, Marchesi JR, Vergis N. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. *Therap Adv Gastroenterol.* 2020 Oct 16;13:1756284820942616. doi: 10.1177/1756284820942616. PMID: 33149761; PMCID: PMC7580143.
46. Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, **Thursz** MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. *PLoS One.* 2020 Oct 8;15(10):e0240400. doi: 10.1371/journal.pone.0240400. PMID: 33031439; PMCID: PMC7544083.
47. Forlano R, Mullish BH, Maurice JB, **Thursz** MR, Goldin RD, Manousou P. NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials. *J Hepatol.* 2020 Oct 2:S0168-8278(20)33596-0. doi: 10.1016/j.jhep.2020.08.025. Epub ahead of print. PMID: 33012546.
48. Maurice J, Lett AM, Skinner C, Lim A, Richardson M, Thomas AP, Summers PA, Vyas K, Tadbier AW, Vilar R, Kuimova MK, Miodragovic S, Vergis N, Kelly P, Cordeiro MF, Hoare J, Darzi A, Goldin R, **Thursz** M, Thompson AJ. Transcutaneous fluorescence spectroscopy as a tool for non-invasive monitoring of gut function: first clinical experiences. *Sci Rep.* 2020 Sep 30;10(1):16169. doi: 10.1038/s41598-020-73149-2. PMID: 32999336; PMCID: PMC7527451.
49. Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista- Leite R, Hirnschall G, Hoen E', Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, **Thursz** M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. *J Hepatol.* 2020 Sep 22:S0168-8278(20)33625-4. doi: 10.1016/j.jhep.2020.09.013. Epub ahead of print. PMID: 32971137; PMCID: PMC7505744.
50. Cohen D, Ghosh S, Shimakawa Y, Ramou N, Garcia PS, Dubois A, Guillot C, Kakwata-Nkor Deluce N, Tilloy V, Durand G, Voegelé C, Ndow G, d'Alessandro U, Brochier-Armanet C, Alain S, Le Calvez-Kelm

- F, Hall J, Zoulim F, Mendy M, **Thursz** M, Lemoine M, Chemin I. Hepatitis B virus preS2Δ38-55 variants: A newly identified risk factor for hepatocellular carcinoma. *JHEP Rep.* 2020 Jul 11;2(5):100144. doi: 10.1016/j.jhepr.2020.100144. PMID: 32904132; PMCID: PMC7452365.
51. Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, **Thursz** MR, Marchesi JR, Mullish BH. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent *Clostridioides difficile* infection and beyond: the contribution of gut microbial-derived metabolites. *Gut Microbes.* 2020 Nov 9;12(1):1810531. doi: 10.1080/19490976.2020.1810531. PMID: 32893721; PMCID: PMC7524310.
52. Kaura A, Sterne JAC, Trickey A, Abbott S, Mulla A, Glampson B, Panoulas V, Davies J, Woods K, Omigie J, Shah AD, Channon KM, Weber JN, **Thursz** MR, Elliott P, Hemingway H, Williams B, Asselbergs FW, O'Sullivan M, Lord GM, Melikian N, Johnson T, Francis DP, Shah AM, Perera D, Kharbanda R, Patel RS, Mayet J. Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. *Lancet.* 2020 Aug 29;396(10251):623-634. doi: 10.1016/S0140-6736(20)30930-2. PMID: 32861307; PMCID: PMC7456783.
53. Angelis A, **Thursz** M, Ratzu V, O'Brien A, Serfaty L, Canbay A, Schiefke I, Costa JBE, Lecomte P, Kanavos P. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. *Med Decis Making.* 2020 Aug;40(6):830-845. doi: 10.1177/0272989X20940672. PMID: 32845234; PMCID: PMC7457462.
54. Hanley B, Naresh KN, Roufousse C, Nicholson AG, Weir J, Cooke GS, Thursz M, Manousou P, Corbett R, Goldin R, Al-Sarraj S, Abdolrasouli A, Swann OC, Baillon L, Penn R, Barclay WS, Viola P, Osborn M. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *Lancet Microbe.* 2020 Oct;1(6):e245-e253. doi: 10.1016/S2666-5247(20)30115-4. Epub 2020 Aug 20. PMID: 32844161; PMCID: PMC7440861.
55. Kim JU, Majid A, Judge R, Crook P, Nathwani R, Selvapatt N, Lovendoski J, Manousou P, **Thursz** M Dhar A, Lewis H, Vergis N, Lemoine M. Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder. *Lancet Gastroenterol Hepatol.* 2020 Aug 4:S2468-1253(20)30251-X. doi: 10.1016/S2468-1253(20)30251-X. Epub ahead of print. PMID: 32763197; PMCID: PMC7403133.
56. Mohamed Z, Scott N, Al-Kurdi D, Selvapatt N, **Thursz** MR, Lemoine M, Brown AS, Nayagam S. Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England. *Liver Int.* 2020 Aug 4. doi: 10.1111/liv.14628. Epub ahead of print. PMID: 32750192.
57. Lazarus JV, Picchio CA, Nayagam S, Ratzan S, **Thursz** M. Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination. *J Hepatol.* 2020 Jul 24;73(3):490–2. doi: 10.1016/j.jhep.2020.06.008. Epub ahead of print. PMID: 32732061; PMCID: PMC7383146.

58. Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, **Thursz** M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M. Global hepatitis C elimination: an investment framework. *Lancet Gastroenterol Hepatol*. 2020 Jul 27:S2468-1253(20)30010-8. doi: 10.1016/S2468-1253(20)30010-8. Epub ahead of print. PMID: 32730786.
59. Bernsmeier C, Cavazza A, Fatourou EM, Theocharidou E, Akintimehin A, Baumgartner B, Dhar A, Auzinger G, **Thursz** M, Bernal W, Wendon JA, Karvellas CJ, Antoniadou CG, McPhail MJW. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. *Aliment Pharmacol Ther*. 2020 Jul 19. doi: 10.1111/apt.15932. Epub ahead of print. PMID: 32683724.
60. Ghani R, Mullish BH, McDonald JAK, Ghazy A, Williams HRT, Brannigan ET, Mookerjee S, Satta G, Gilchrist M, Duncan N, Corbett R, Innes AJ, Pavlů J, **Thursz** MR, Davies F, Marchesi JR. Disease prevention not decolonization - a model for fecal microbiota transplantation in patients colonized with multidrug-resistant organisms. *Clin Infect Dis*. 2020 Jul 18:ciaa948. doi: 10.1093/cid/ciaa948. Epub ahead of print. PMID: 32681643.
61. Dhanda A, Atkinson S, Vergis N, Enki D, Fisher A, Clough R, Cramp M, **Thursz** M. Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis. *Aliment Pharmacol Ther*. 2020 Aug;52(3):537-544. doi: 10.1111/apt.15880. Epub 2020 Jun 23. PMID: 32573823.
62. Zhou H, Sealock JM, Sanchez-Roige S, Clarke TK, Levey DF, Cheng Z, Li B, Polimanti R, Kember RL, Smith RV, Thygesen JH, Morgan MY, Atkinson SR, **Thursz** MR, Nyegaard M, Mattheisen M, Børghlum AD, Johnson EC, Justice AC, Palmer AA, McQuillin A, Davis LK, Edenberg HJ, Agrawal A, Kranzler HR, Gelernter J. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. *Nat Neurosci*. 2020 Jul;23(7):809-818. doi: 10.1038/s41593-020-0643-5. Epub 2020 May 25. PMID: 32451486.
63. Nayagam S, Chan P, Zhao K, Sicuri E, Wang X, Jia J, Wei L, Walsh N, Rodewald LE, Zhang G, Ailing W, Zhang L, Chang JH, Hou W, Qiu Y, Sui B, Xiao Y, Zhuang H, **Thursz** MR, Scano F, Low-Beer D, Schwartländer B, Wang Y, Hallett TB. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. *Clin Infect Dis*. 2020 Apr 7:ciaa134. doi: 10.1093/cid/ciaa134. Epub ahead of print. PMID: 32255486.
64. Kaura A, Arnold AD, Panoulas V, Glampson B, Davies J, Mulla A, Woods K, Omigie J, Shah AD, Channon KM, Weber JN, **Thursz** MR, Elliott P, Hemingway H, Williams B, Asselbergs FW, O'Sullivan M, Lord GM, Melikian N, Lefroy DC, Francis DP, Shah AM, Kharbanda R, Perera D, Patel RS, Mayet J. Prognostic significance

- of troponin level in 3121 patients presenting with atrial fibrillation (The NIHR Health Informatics Collaborative TROP-AF study). *J Am Heart Assoc.* 2020 Apr 7;9(7):e013684. doi: 10.1161/JAHA.119.013684. Epub 2020 Mar 26. PMID: 32212911.
65. Forlano R, Mullish BH, Nathwani R, Dhar A, **Thursz** M, Manousou P. Non-Alcoholic Fatty Liver Disease and Vascular Disease. *Curr Vasc Pharmacol.* 2020 Mar 17. doi: 10.2174/1570161118666200318103001. Epub ahead of print. PMID: 32188385.
66. Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, Mukherjee SK, **Thursz** M, Wong CN, Sharma R, Rimassa L. Immune-based therapies for hepatocellular carcinoma. *Oncogene.* 2020 Apr;39(18):3620-3637. doi: 10.1038/s41388-020-1249-9. Epub 2020 Mar 10. PMID: 32157213; PMCID: PMC7190571.
67. Daunt A, Perez-Guzman PN, Liew F, Hauck K, Costelloe CE, Thursz MR, Cooke G, Nayagam S. Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. *J Infect.* 2020 Jun 21:S0163-4453(20)30430-8. doi: 10.1016/j.jinf.2020.06.049. Epub ahead of print. PMID: 32579980; PMCID: PMC7306204.
68. Perez-Guzman PN, Daunt A, Mukherjee S, Crook P, Forlano R, Kont MD, Løchen A, Vollmer M, Middleton P, Judge R, Harlow C, Soubieres A, Cooke G, White PJ, Hallett TB, Aylin P, Ferguson N, Hauck K, **Thursz** MR, Nayagam S. Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study. *Clin Infect Dis.* 2020 Aug 7:ciaa1091. doi: 10.1093/cid/ciaa1091. Epub ahead of print. PMID: 32766823.
69. Atkinson SR, Hamesch K, Spivak I, Guldiken N, Cabezas J, Argemi J, Theurl I, Zoller H, Cao S, Mathurin P, Shah VH, Trautwein C, Bataller R, **Thursz** MR, Strnad P. Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. *Am J Gastroenterol.* 2020 Jan 24. doi: 10.14309/ajg.0000000000000492. [Epub ahead of print] PubMed PMID: 31985531.
70. Forlano R, Mullish BH, Giannakeas N, Maurice JB, Angkathunyakul N, Lloyd J, Tzallas AT, Tsipouras M, Yee M, **Thursz** MR, Goldin RD, Manousou P. High-Throughput, Machine Learning-based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients with Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol.* 2019 Dec 27. pii: S1542-3565(19)31505-8. doi: 10.1016/j.cgh.2019.12.025. [Epub ahead of print] PubMed PMID: 31887451
71. Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, **Thursz** MR. Recent advances in alcohol-related liver disease (ALD): summary of aGut round table meeting. *Gut.* 2019 Dec 26. pii: gutjnl-2019-319720. doi:10.1136/gutjnl-2019-319720. [Epub ahead of print] Review. PubMed PMID: 31879281

72. Mohamed Z, Mbwambo J, Rwegasha J, Mgina N, Doulla B, Mwakale P, Tuailon E, Chevaliez S, Shimakawa Y, Taylor-Robinson SD, **Thursz MR**, Brown AS, Lemoine M. In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania. *Liver Int.* 2019 Nov 28. doi: 10.1111/liv.14315. [Epub ahead of print] PubMed PMID: 31778282
73. Mohamed Z, Al-Kurdi D, Nelson M, Shimakawa Y, Selvapatt N, Lacey J, **Thursz MR**, Lemoine M, Brown AS. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. *Int J Drug Policy.* 2020 Jan;75:102608. doi:10.1016/j.drugpo.2019.102608. Epub 2019 Nov 20. PubMed PMID: 31759307
74. Kaura A, Panoulas V, Glampson B, Davies J, Mulla A, Woods K, Omigie J, Shah AD, Channon KM, Weber JN, **Thursz MR**, Elliott P, Hemingway H, Williams B, Asselbergs F, O'Sullivan M, Kharbanda R, Lord GM, Melikian N, Patel RS, Perera D, Shah AM, Francis DP, Mayet J. Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres. *BMJ.* 2019 Nov 20;367:l6055. doi: 10.1136/bmj.l6055. PubMed PMID: 31748235; PubMed Central PMCID: PMC6865859
75. Lebossé F, Gudd C, Tunc E, Singanayagam A, Nathwani R, Triantafyllou E, Pop O, Kumar N, Mukherjee S, Hou TZ, Quaglia A, Zoulim F, Wendon J, Dhar A, **Thursz M**, Antoniadou CG, Khamri W. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. *EBioMedicine.* 2019 Nov;49:258-268. doi: 10.1016/j.ebiom.2019.10.011. Epub 2019 Oct 31. PubMed PMID: 31678004; PubMed Central PMCID: PMC6945243
76. Schröder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, **Thursz M**, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. *Liver Int.* 2019 Oct;39(10):1818-1836. doi:10.1111/liv.14222. Epub 2019 Sep 4. Review. PubMed PMID: 31433902; PubMed Central PMCID: PMC6790606
77. Vergis N, Atkinson SR, **Thursz MR**. Assessment and Management of Infection in Alcoholic Hepatitis. *Semin Liver Dis.* 2019 Aug 1. doi: 10.1055/s-0039-1693402. [Epub ahead of print] PubMed PMID: 31370067.
78. Forrest EH, Storey N, Sinha R, Atkinson SR, Vergis N, Richardson P, Masson S, Ryder S, **Thursz MR**, Allison M, Fraser A, Austin A, McCune A, Dhanda A, Katarey D, Potts J, Verma S, Parker R, Hayes PC; STOPAH NLR Group. Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. *Aliment Pharmacol Ther.* 2019 Aug;50(4):442-453. doi: 10.1111/apt.15335. Epub 2019 Jul 17. PubMed PMID: 31313853
79. Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey V, Gue JP, Cabezas J, Lozano JJ, Van Booven D, Bell A, Cao S, Verneti LA, Arab JP, Ventura-Cots M, Edmunds LR, Fondevilla C, Stärkel P, Dubuquoy L, Louvet A, Odena G, Gomez JL, Aragon T, Altamirano J, Caballeria J, Jurczak MJ, Taylor DL, Berasain C, Wahlestedt C, Monga SP, Morgan MY, Sancho-Bru P, Mathurin P, Furuya S, Lackner C, Rusyn I, Shah

- VH, **Thursz MR**, Mann J, Avila MA, Bataller R. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. *Nat Commun*. 2019 Jul 16;10(1):3126. doi: 10.1038/s41467-019-11004-3. PubMed PMID: 31311938; PubMed Central PMCID: PMC6635373.
80. Bennett K, Enki DG, **Thursz M**, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high mortality in patients with nonsevere alcoholic hepatitis. *Aliment Pharmacol Ther*. 2019 Jun 23. doi: 10.1111/apt.15376. [Epub ahead of print] Review. PubMed PMID: 31231848.
81. Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, **Thursz M**, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. *Eur J Cancer*. 2019 Jun 4;116:56-66. doi: 10.1016/j.ejca.2019.04.014. [Epub ahead of print] PubMed PMID: 31173963
82. Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceessay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, **Thursz MR**, Lemoine M. Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa. *Clin Infect Dis*. 2019 May 17. pii: ciz412. doi: 10.1093/cid/ciz412. [Epub ahead of print] PubMed PMID: 31102406.
83. Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, **Thursz M**, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV mono-infection independently of the gut microbiome and bacterial translocation. *AIDS*. 2019 Apr 1;33(5):805-814. doi: 10.1097/QAD.0000000000002133. PubMed PMID: 30882489.
84. Abeles RD, Mullish BH, Forlano R, Kimhofer T, Adler M, Tzallas A, Giannakeas N, Yee M, Mayet J, Goldin RD, **Thursz MR**, Manousou P. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. *Aliment Pharmacol Ther*. 2019 Mar 5. doi: 10.1111/apt.15192. [Epub ahead of print] PubMed PMID: 30836450
85. Heffernan A, Cooke GS, Nayagam S, **Thursz M**, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. *Lancet*. 2019 Jan 28. pii: S0140-6736(18)32277-3. doi:10.1016/S0140-6736(18)32277-3. [Epub ahead of print] PubMed PMID: 30704789.
86. Mohamed Z, Kim JU, Magesa A, Kasubi M, Feldman SF, Chevaliez S, Mwakale P, Taylor-Robinson SD, **Thursz MR**, Shimakawa Y, Rwegasha J, Lemoine M. High prevalence and poor linkage to care of transfusion-transmitted infections among blood donors in Dar-es-Salaam, Tanzania. *J Viral Hepat*. 2019 Feb 3. doi: 10.1111/jvh.13073. [Epub ahead of print] PubMed PMID: 30712273.
87. Vergis N, Atkinson SR, **Thursz MR**. The future of therapy for alcoholic hepatitis - Beyond corticosteroids. *J Hepatol*. 2019 Feb 18. pii: S0168-8278(19)30030-3. doi: 10.1016/j.jhep.2019.01.016. [Epub ahead of print] PubMed PMID: 30791978.
88. Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, Glegola-Madejska I, Williams HRT, Holmes E, Clarke TB, **Thursz MR**, Marchesi JR. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the

treatment of recurrent *Clostridioides difficile* infection. *Gut*. 2019 Feb 11. pii: gutjnl-2018-317842. doi: 10.1136/gutjnl-2018-317842. [Epub ahead of print] PubMed PMID: 30816855.

89. Abeles RD, Mullish BH, Forlano R, Kimhofer T, Adler M, Tzallas A, Giannakeas N, Yee M, Mayet J, Goldin RD, **Thursz MR**, Manousou P. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. *Aliment Pharmacol Ther*. 2019 Mar 5. doi: 10.1111/apt.15192. [Epub ahead of print] PubMed PMID: 30836450
90. Mathurin P, **Thursz M**. Endpoints and patient stratification in clinical trials for alcoholic hepatitis. **Journal of Hepatology**. 2019 Feb;70(2):314-318.
91. Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, **Thursz M**, Lemoine M. Monocyte-Macrophage activation is associated with NAFLD and liver fibrosis in HIV mono-infection independently of the gut microbiome and bacterial translocation. *AIDS* 2019 Jan 14. doi: 10.1097/QAD.0000000000002133
92. Szabo G, Kamath PS, Shah VH, **Thursz M**, Mathurin P; EASL-AASLD Joint Meeting. Alcohol Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. **Hepatology**. 2019 Jan 15. doi: 10.1002/hep.30369.
93. Zakaria ZA, Knapp S, Hashem M, Zaghla H, **Thursz M**, Waked I, Abdelwahab S. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. **Journal of Immunology Research**. 2018 Nov 6. doi: 10.1007/s12026-018-9035-2.
94. Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, **Thursz MR**, Allison M; STOPAH Trial Management Group. Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. **Journal of Hepatology**. 2018 Nov;69(5):1200-1201.
95. Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, **Thursz M**, Lemoine M. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. **Journal of Hepatology**. 2018 Oct;69(4):776-784.
96. Chambers ES, Byrne CS, Ruyendo A, Morrison DJ, Preston T, Tedford C, Bell JD, Thomas L, Akbar AN, Riddell NE, Sharma R, **Thursz MR**, Manousou P, Frost G. The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. *Diabetes, Obesity and Metabolism*. 2018 Aug 11. doi: 10.1111/dom.13500.
97. Lazarus JV, Pericàs JM, Colombo M, Ninburg M, Wiktor S, **Thursz M**. Viral hepatitis: "E" is for equitable elimination. **Journal of Hepatology**. 2018 Oct;69(4):762-764.
98. McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J, Kao D, Holmes E, Li JV, Clarke TB, **Thursz MR**, Marchesi JR. Inhibiting Growth of *Clostridioides difficile* by Restoring Valerate, Produced by the Intestinal Microbiota. **Gastroenterology**. 2018 Jul 16. pii: S0016-5085(18)34771-1.
99. Lazarus JV, Safreed-Harmon K, **Thursz MR**, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. **Seminars in Liver Diseases**. 2018 Jul 9. 38:181–192.
100. Mohamed Z, Rwegasha J, Kim JU, Shimakawa Y, Poiteau L, Chevaliez S, Bhagani S, Taylor-Robinson SD, **Thursz MR**, Mbwambo J, Lemoine M. The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. **Journal of Viral Hepatitis**. 2018 Jul 3. doi: 10.1111/jvh.12966.
101. Dhar A, Sadiq F, Anstee QM, Levene AP, Goldin RD, **Thursz MR**. Thrombin and factor Xa link the coagulation system with liver fibrosis. **BMC Gastroenterology**. 2018 May 8;18(1):60.

102. Louvet A, **Thursz MR**, Kim DJ, Labreuche J, Atkinson S, Sidhu SS, O'Grady JG, Akriviadis E, Sinakos E, Carithers RL Jr, Ramond MJ, Maddrey WC, Morgan TR, Duhamel A, Mathurin P. Corticosteroids Reduce Risk of Death Within 28 Days for Patients with Severe Alcoholic Hepatitis, Compared with Pentoxifylline or Placebo—a Meta-analysis of Individual Data. **Gastroenterology**. 2018 May 5. pii: S0016-5085(18)34495-0.
103. Mullish BH, Pechlivanis A, Barker GF, **Thursz MR**, Marchesi JR, McDonald JAK. Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease. **Methods**. 2018 Apr 26. pii: S1046-2023(17)30422-X.
104. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. **Journal of Hepatology**. 2018 Jul;69(1):154-181.
105. Ortega-Prieto AM, Skelton JK, Wai SN, Large E, Lussignol M, Vizcay-Barrena G, Hughes D, Fleck RA, **Thursz M**, Catanese MT, Dorner M. 3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection. **Nature Communications**. 2018 Feb 14;9(1):682.
106. Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, **Thursz MR**, Allison M; STOPAH Trial Management Group. Application of Prognostic Scores in The Stopah Trial: Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis. **Journal of Hepatology**. 2017 Nov 21. pii: S0168-8278(17)32440-6.
107. Nayagam S, Sicuri E, Lemoine M, Easterbrook P, Conteh L, Hallett TB, **Thursz M**. Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. **BMC Infectious Diseases**. 2017 Nov 1;17(Suppl 1):692.
108. Mullish BH, McDonald JAK, **Thursz MR**, Marchesi JR. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. **Hepatology**. 2017 Oct;66(4):1354-1355.
109. Kumar A, Gangadharan B, Cobbold J, **Thursz M**, Zitzmann N. Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example. **Scientific Reports**. 2017 Sep 21;7(1):12072.
110. Mohamed Z, Mbwambo J, Shimakawa Y, Poiteau L, Chevaliez S, Pawlotsky JM, Rwegasha J, Bhagani S, Taylor-Robinson SD, Makani J, **Thursz MR**, Lemoine M. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania. **Journal of the International AIDS Society**. 2017 Sep 19;20(1):21856.
111. Lazarus JV, Wiktor S, Colombo M, **Thursz M**. EASL International Liver Foundation. Micro-elimination - A path to global elimination of hepatitis C. **Journal of Hepatology**. 2017 Jul 28. pii: S0168-8278(17)32141-4.
112. Atkinson SR, Vergis N, Louvet A, **Thursz MR**. Universal screening of acute medical admissions for excess alcohol consumption: What's the misuse? **Journal of Hepatology**. 2017 Jul 12. pii: S0168-8278(17)32076-7.
113. Ndow G, Gore ML, Shimakawa Y, Suso P, Jatta A, Tamba S, Sow A, Touré-Kane C, Sadiq F, Sabally S, Njie R, **Thursz MR**, Lemoine M. Hepatitis B testing and treatment in HIV patients in The Gambia—Compliance with international guidelines and clinical outcomes. **PLoS One**. 2017 Jun 14;12(6):e0179025.
114. Bernsmeier C, Triantafyllou E, Brenig R, Lebosse FJ, Singanayagam A, Patel VC, Pop OT, Khamri W, Nathwani R, Tidswell R, Weston CJ, Adams DH, **Thursz MR**, Wendon JA, Antoniadou CG. CD14(+)CD15(-)HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. **Gut**. 2017 Jun 7. pii: gutjnl-2017-314184.
115. Triantafyllou E, Pop OT, Possamai LA, Wilhelm A, Liaskou E, Singanayagam A, Bernsmeier C, Khamri W, Petts G, Dargue R, Davies SP, Tickle J, Yuksel M, Patel VC, Abeles RD, Stamataki Z,

- Curbishley SM, Ma Y, Wilson ID, Coen M, Woollard KJ, Quaglia A, Wendon J, **Thursz MR**, Adams DH, Weston CJ, Antoniades CG. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. **Gut**. 2017 Apr 27. pii: gutjnl-2016-313615.
116. Cobbold JFL, Atkinson S, Marchesi JR, Smith A, Wai SN, Stove J, Shojaee-Moradie F, Jackson N, Umpleby AM, Fitzpatrick J, Thomas EL, Bell JD, Holmes E, Taylor-Robinson SD, Goldin RD, Yee MS, Anstee QM, **Thursz MR**. Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study. **Hepatology Research**. 2018 Jan;48(1):69-77
117. Maurice JB, Patel A, Scott AJ, Patel K, **Thursz M**, Lemoine M. Prevalence and risk factors of non-alcoholic fatty liver disease in HIV-monoinfection: a systematic review and meta-analysis. **AIDS**. 2017 Jul 17;31(11):1621-1632
118. Khamri W, Abeles RD, Hou TZ, Anderson AE, El-Masry A, Triantafyllou E, Bernsmeier C, Larsen FS, Singanayagam A, Kudo N, Possamai LA, Lebosse F, Auzinger G, Bernal W, Willars C, Weston CJ, Lombardi G, Wendon J, **Thursz M**, Antoniades CG. Increased Expression of CTLA4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients with Acute Liver Failure. **Gastroenterology**. 2017 Mar 28. pii: S0016-5085(17)30332-3.
119. Dhar A, Mullish BH, **Thursz MR**. Anticoagulation in chronic liver disease. **Journal of Hepatology**. 2017 Jan 12. pii: S0168-8278(17)30010-7. doi: 10.1016/j.jhep.2017.01.006.
120. Atkinson SR, Way MJ, McQuillin A, Morgan MY, **Thursz MR**. Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. **Journal of Hepatology**. 2017 Jul;67(1):120-127
121. Elsharkawy A, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, Said M, Motawea I, El Demerdash T, Seif S, Gaballah A, El Shazly Y, Makhoulf MA, Waked I, Abdelaziz AO, Yosry A, El Serafy M, **Thursz M**, Doss W, Esmat G. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. **Alimentary Pharmacology & Therapeutics**. 2017 Mar;45(5):681-687.
122. Howell JA, Khan SA, Knapp S, **Thursz MR**, Sharma R. The clinical role of circulating free tumor DNA in gastrointestinal malignancy. **Translational Research**. 2016 Dec 22. pii: S1931-5244(16)30461-3.
123. Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, Forrest EH, Masson S, McCune A, Patch D, Ryder S, Wright M, **Thursz MR**. In Patients with Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, Associated with High Circulating Levels of Bacterial DNA. **Gastroenterology**. 2016 Dec 30. pii: S0016-5085(16)35533-0.
124. McEwan P, Selvapatt N, Brown A, **Thursz M**, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. **European Journal of Gastroenterology & Hepatology**. 2017 Feb;29(2):208-214
125. Ghosh S, Sow A, Guillot C, Jeng A, Ndow G, Njie R, Toure S, Diop M, Mboup S, Kane CT, Lemoine M, **Thursz M**, Zoulim F, Mendy M, Chemin I. Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries. **Journal of Viral Hepatitis**. 2016 Nov;23(11):897-904.
126. Lemoine M, **Thursz MR**. Field battle against hepatitis B infection and HCC in Africa. **Journal of Hepatology**. 2016 Oct 19. pii: S0168-8278(16)30578-5.
127. Nayagam S, **Thursz M**, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB. Requirements for global elimination of hepatitis B: a modelling study. **Lancet Infectious Diseases**. 2016 Sep 13. pii: S1473-3099(16)30204-3.

128. Selvapatt N, Ward T, Harrison L, Lombardini J, **Thursz M**, McEwan P, Brown A. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit. **Liver International**. 2016 Aug 27 p 345-353
129. Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, **Thursz M**. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. **Lancet Global Health**. 2016 Aug;4(8):e568-78.
130. Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, Ghosh S, Njai HF, Jeng A, Sow A, Toure-Kane C, Mboup S, Suso P, Tamba S, Jatta A, Sarr L, Kambi A, Stanger W, Nayagam S, Howell J, Mpabanzi L, Nyan O, Corrah T, Whittle H, Taylor-Robinson SD, D'Alessandro U, Mendy M, **Thursz MR**; PROLIFICA investigators. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. **Lancet Global Health**. 2016 Aug;4(8):e559-67.
131. Gratton J, Phetcharaburanin J, Mullish BH, Williams HR, **Thursz M**, Nicholson JK, Holmes E, Marchesi JR, Li JV. Optimized Sample Handling Strategy for Metabolic Profiling of Human Faeces. **Analytical Chemistry**. 2016 May 3;88(9):4661-8.
132. **Thursz M**, Morgan TR. Treatment of Severe Alcoholic Hepatitis. **Gastroenterology**. 2016 Jun;150(8):1823-34.
133. Lemoine M, **Thursz M**, Mallet V, Shimakawa Y. Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference. **Gut**. 2016 Feb 26. pii: gutjnl-2016-311554.
134. **Thursz M**, Forrest E, Roderick P, Day C, Austin A, O'Grady J, Ryder S, Allison M, Gleeson D, McCune A, Patch D, Wright M, Masson S, Richardson P, Vale L, Mellor J, Stanton L, Bowers M, Ratcliffe I, Downs N, Kirkman S, Homer T, Ternent L. The clinical effectiveness and cost-effectiveness of STeroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. **Health Technology Assessment**. 2015 Dec;19(102):1-104.
135. Shimakawa Y, Toure-Kane C, Mendy M, **Thursz M**, Lemoine M. Mother-to-child transmission of hepatitis B in sub-Saharan Africa. **Lancet Infectious Diseases**. 2016 Jan;16(1):19-20.
136. Vergis N, Khamri W, Beale K, Sadiq F, Aletrari MO, Moore C, Atkinson SR, Bernsmeier C, Possamai LA, Petts G, Ryan JM, Abeles RD, James S, Foxton M, Hogan B, Foster GR, O'Brien AJ, Ma Y, Shawcross DL, Wendon JA, Antoniadis CG, **Thursz MR**. Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. **Gut**. 2016 Feb 9. pii: gutjnl-2015-310378.
137. Puri P, **Thursz M**. Intensive Enteral Nutrition in Alcoholic Hepatitis: More Food for Thought. **Gastroenterology**. 2016 Apr;150(4):803-5.
138. **Thursz M**, Morgan TR. Treatment of Severe Alcoholic Hepatitis. **Gastroenterology**. 2016 Jun;150(8):1823-34.
139. Gratton J, Phetcharaburanin J, Mullish BH, Williams HR, **Thursz M**, Nicholson JK, Holmes E, Marchesi JR, Li JV. Optimized Sample Handling Strategy for Metabolic Profiling of Human Faeces. **Analytical Chemistry**. 2016 May 3;88(9):4661-8.
140. Shimakawa Y, Njai HF, Takahashi K, Berg L, Ndow G, Jeng-Barry A, Ceesay A, Tamba S, Opoku E, Taal M, Akbar SM, Arai M, D'Alessandro U, Taylor-Robinson SD, Njie R, Mishiro S, **Thursz MR**, Lemoine M. Hepatitis E virus infection and acute-on-chronic liver failure in West Africa: a case-control study from The Gambia. **Alimentary Pharmacology & Therapeutics**. 2016 Feb;43(3):375-84
141. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichtler S, Eholié S, Boëlle PY, Fontanet A; HCV epidemiology in Africa group. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. **Journal of Viral Hepatitis**. 2016 Apr;23(4):244-55

142. **Thursz M**, Lacombe K. Breaking Down Barriers to Care in Hepatitis C Virus Infection. **Journal of Infectious Diseases**. 2016 Apr 1;213(7):1055-6.
143. Blackmore LJ, Ryan JM, Huang X, Hussain M, Triantafyllou E, Vergis N, Vijay GM, Antoniadou CG, **Thursz MR**, Jassem W, Vergani D, Shawcross DL, Ma Y. Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. **Lancet**. 2015 Feb 26;385
144. Howell J, Ladepe NG, Lemoine M, Nayagam S, Toure PS, Diop MM, Daveiga Joao Armindo, Sall AS, Lo G, Crossey MM, **Thursz MR**, Taylor-Robinson SD, Ka MM. Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project--a collaborative study of hepatitis B-related liver disease in West Africa. **South African Medical Journal**. 2015 Mar;105(3):185-6.
145. Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, Jatta A, Jeng-Barry A, Wegmuller R, Moore SE, Baldeh I, Taal M, D'Alessandro U, Whittle H, Njie R, **Thursz M**, Mendy M. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. **Gut**. 2015 Jul 16. pii: gutjnl-2015-309892.
146. **Thursz MR**, Forrest EH, Ryder S; STOPAH investigators. Prednisolone or Pentoxifylline for Alcoholic Hepatitis. **The New England Journal of Medicine**. 2015 Jul 16;373(3):282-3
147. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, Goldin R, Njai HF, Ndow G, Taal M, Cooke G, D'Alessandro U, Vray M, Mbaye PS, Njie R, Mallet V, **Thursz M**. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. **Gut**. 2015 Jun 24. pii: gutjnl-2015-309260.
148. Howell J, Ladepe NG, Nayagam S, Lemoine M, Garside DA, Crossey MM, Okeke E, Njie R, Ka MM, Taal M, **Thursz MR**, Taylor-Robinson SD. PROLIFICA: a story of West African clinical and research collaborations to target hepatitis B-related hepatocellular carcinoma in West Africa. **Quarterly Journal of Medicine**. 2016 Jun;109(6):373-375
149. Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, **Thursz MR**, Loomba R, Shah VH. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. **Gastroenterology**. 2015 Oct;149(4):958-970
150. Andersson MI, Rajbhandari R, Kew MC, Vento S, Preiser W, Hoepelman AI, Theron G, Cotton M, Cohn J, Glebe D, Lesi O, **Thursz M**, Peters M, Chung R, Wiysonge C. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. **Lancet Global Health**. 2015 Jul;3(7):e358-9.
151. Selvapatt N, Ward T, Bailey H, Bennett H, Thorne C, See LM, Tudor-Williams G, **Thursz M**, McEwan P, Brown A. Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre. **Journal of Hepatology**. 2015 Oct;63(4):797-804.
152. **Thursz MR**, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. **The New England Journal of Medicine**. 2015 Apr 23;372(17):1619-28.
153. Kimhofer T, Fye H, Taylor-Robinson S, **Thursz M**, Holmes E. Proteomic and metabolomic biomarkers for hepatocellular carcinoma: a comprehensive review. **British Journal of Cancer**. 2015 Mar 31;112:1141-1156
154. Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I, **Thursz M**, Abdelwahab SF. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. **Hepatology International**. 2015 Apr;9(2):251-7.
155. Shimakawa Y, Lemoine M, Bottomley C, Njai HF, Ndow G, Jatta A, Tamba S, Bojang L, Taal M, Nyan O, D'Alessandro U, Njie R, **Thursz M**, Hall AJ. Birth order and risk of hepatocellular carcinoma

- in chronic carriers of hepatitis B virus: a case-control study in The Gambia. **Liver International**. 2015 Oct;35(10):2318-26.
156. Selvapatt N, Brown A, **Thursz M**. Early diagnosis and treatment: the goal of hepatitis C screening. **British Medical Journal**. 2015 Feb 24;350:h635.
157. Lemoine M, **Thursz M**. Viral hepatitis: Scaling up HCV treatment in resource-limited countries. **Nature Reviews Gastroenterology & Hepatology**. 2015 Apr;12(4):193-4.
158. Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, Sow A, Lo G, Toure-Kane C, Tanaka J, Taal M, D'alessandro U, Njie R, **Thursz M**, Lemoine M. Validation of Rapid Point-of-Care (POC) Tests for Detection of Hepatitis B Surface Antigen in Field and Laboratory Settings in the Gambia, Western Africa. **Journal of Clinical Microbiology**. 2015 Apr;53(4):1156-63.
159. Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ, Curbishley S, Sadiq F, Vergis N, Khamri W, Bernal W, Auzinger G, Heneghan M, Ma Y, Jassem W, Heaton ND, Adams DH, Quaglia A, **Thursz MR**, Wendon J, Antoniadou CG. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. **Gastroenterology**. 2015 Mar;148(3):603-615.e14
160. Markwick LJ, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, **Thursz M**, Evans A, Wright G, Tarff S, O'Grady J, Williams R, Shawcross DL, Chokshi S. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. **Gastroenterology**. 2015 Mar;148(3):590-602.e10
161. Shimakawa Y, Lemoine M, Mendy M, Njai HF, D'Alessandro U, Hall A, **Thursz M**, Njie R. Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the Gambia, west Africa. **Tropical Medicine and Health**. 2014 Jun;42(2 Suppl):59-64
162. Knapp S, Meghjee N, Cassidy S, Jamil K, **Thursz M**. Detection of allele specific differences in IFNL3 (IL28B) mRNA expression. **BMC Medical Genetics**. 2014 Oct 5;15(1):104
163. Possamai LA, McPhail MJ, Khamri W, Wu B, Concas D, Harrison M, Williams R, Cox RD, Cox IJ, Anstee QM, **Thursz MR**. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. **Liver International**. 2015 Mar;35(3):764-73
164. Shimakawa Y, Takao Y, Anderson ST, Taal M, Yamaguchi T, Giana L, Ndow G, Sarr L, Kambi A, Njai HF, Bottomley C, Nyan O, Sabally S, D'Alessandro U, Taylor Robinson SD, **Thursz M**, Lemoine M, Njie R. The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia, West Africa. **Palliative Medicine**. 2015 Feb;29(2):184-5.
165. Mullish BH, Marchesi JR, **Thursz MR**, Williams HR. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. **Quarterly Journal of Medicine**. 2015 May;108(5):355-9
166. Howell J, Van Gemert C, Lemoine M, **Thursz M**, Hellard M. An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories. **Journal of Gastroenterology & Hepatology**. 2014 Nov;29(11):1854-66
167. Ladep NG, Dona AC, Lewis MR, Crossey MM, Lemoine M, Okeke E, Shimakawa Y, Duguru M, Njai HF, Fye HK, Taal M, Chetwood J, Kasstan B, Khan SA, Garside DA, Wijeyesekera A, Thillainayagam AV, Banwat E, **Thursz MR**, Nicholson JK, Njie R, Holmes E, Taylor-Robinson SD. Discovery and validation of urinary metabolites for the diagnosis of hepatocellular carcinoma (HCC) in West Africans. **Hepatology**. 2014 Oct;60(4):1291-301
168. Howell J, Lemoine M, **Thursz M**. Prevention of materno-foetal transmission of hepatitis B in sub-Saharan Africa: the evidence, current practice and future challenges. **Journal of Viral Hepatitis**. 2014 Jun;21(6):381-96.

169. Lemoine M, **Thursz M**. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. **Seminars in Liver Diseases**. 2014 Feb;34(1):89-97.
170. Possamai LA, **Thursz MR**, Wendon JA, Antoniades CG. Modulation of monocyte/macrophage function: A therapeutic strategy in the treatment of acute liver failure. **Journal of Hepatology**. 2014 Aug;61(2):439-45
171. Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, **Thursz M**, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. **Systematic Review**. 2014 Mar 7;3:21.
172. Lemoine M, Shimakawa Y, Nayagam S, Njie R, **Thursz M**. Commentary: how long does one need to fast before a Fibroscan examination? Authors' reply. **Alimentary Pharmacology & Therapeutics**. 2014 Mar;39(5):541-2.
173. Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, Goldin R, Ingiliz P, Taal M, Nyan O, Corrah T, D'Alessandro U, **Thursz M**. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. **Alimentary Pharmacology & Therapeutics**. 2014 Jan;39(2):188-96.
174. Ezzikouri S, Rebbani K, Fakhir FZ, Alaoui R, Nadir S, Diepolder H, **Thursz M**, Khakoo SI, Benjelloun S. The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and decrease of viral loads. **Clinical Microbiology and Infection**. 2014 May;20(5):O325-32.
175. Antoniades CG, Khamri W, Abeles RD, Taams LS, Triantafyllou E, Possamai LA, Bernsmeier C, Mitry RR, O'Brien A, Gilroy D, Goldin R, Heneghan M, Heaton N, Jassem W, Bernal W, Vergani D, Ma Y, Quaglia A, Wendon J, **Thursz M**. Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. **Hepatology**. 2014 Apr;59(4):1564-76.
176. Abdelrahman T, Hughes J, Main J, McLauchlan J, **Thursz M**, Thomson E. Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment. **Hepatology**. 2015 Jan;61(1):88-97
177. **Thursz M**, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. **Nature Reviews Gastroenterology & Hepatology**. 2014 Jan;11(1):28-35
178. Lemoine M, **Thursz M**, Njie R, Dusheiko G. Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. **Liver International**. 2014 Jan;34(1):12-5
179. Robinson O, Want E, Coen M, Kennedy R, van Den Bosch C, Gebrehawaria Y, Kudo H, Sadiq F, Goldin RD, Hauser ML, Fenwick A, Toledano MB, **Thursz MR**. Hirri Valley Liver Disease: A disease associated with exposure to pyrrolizidine alkaloids and DDT. **Journal of Hepatology**. 2014 Jan;60(1):96-102
180. Forrest E, Mellor J, Stanton L, Bowers M, Ryder P, Austin A, Day C, Gleeson D, O Grady J, Masson S, McCune A, Patch D, Richardson P, Roderick P, Ryder S, Wright M, **Thursz M**. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. **Trials**. 2013 Aug 19;14(1):262.
181. Possamai LA, McPhail MJ, Quaglia A, Zingarelli V, Abeles RD, Tidswell R, Puthuchery Z, Rawal J, Karvellas CJ, Leslie EM, Hughes RD, Ma Y, Jassem W, Shawcross DL, Bernal W, Dharwan A, Heaton ND, **Thursz M**, Wendon JA, Mitry RR, Antoniades CG. Character and Temporal Evolution of Apoptosis in Acetaminophen-Induced Acute Liver Failure. **Critical Care Medicine**. 2013 Aug 14.

182. Cooke GS, Lemoine M, **Thursz M**, Gore C, Swan T, Kamarulzaman A, Ducros P, Ford N. Viral hepatitis and the Global Burden of Disease: a need to regroup. **Journal of Viral Hepatitis**. 2013 Sep;20(9):600-1.
183. Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, Dominguez A, Donoghoe M, Elzouki AN, Ben-Alaya Bouafif N, Esmat G, Esteban R, Fabri M, Fenton K, Goldberg D, Goulis I, Hadjichristodoulou T, Hatzigeorgiou T, Hamouda O, Hasurdjiev S, Hughes S, Kautz A, Malik M, Manolakopoulos S, Matičič M, Papatheodoridis G, Peck R, Peterle A, Potamitis G, Prati D, Roudot-Thoraval F, Reic T, Sharara A, Shennak M, Shiha G, Shouval D, Sočan M, Thomas H, **Thursz M**, Tosti M, Trépo C, Vince A, Vounou E, Wiessing L, Manns M. The state of hepatitis B and C in the mediterranean and balkan countries: report from a summit conference. **Journal of Viral Hepatitis**. 2013 Aug;20 Suppl 2:1-20.
184. Goldsworthy M, Absalom NL, Schröter D, Matthews HC, Bogani D, Moir L, Long A, Church C, Hugill A, Anstee QM, Goldin R, **Thursz M**, Hollfelder F, Cox RD. Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. **PLoS One**. 2013 Jun 24;8(6):e61870.
185. Leggewie M, Sreenu VB, Abdelrahman T, Leitch EC, Wilkie GS, Klymenko T, Muir D, **Thursz M**, Main J, Thomson EC. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. **AIDS**. 2013 Jun 13. V27:15 p2485-2488.
186. Lemoine M, Nayagam S, **Thursz M**. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. **Future Virology**. 2013 April; 8(4): 371–380.
187. Genetic Variation in the Interleukin-28B Gene Is Associated with Spontaneous Clearance and Progression of Hepatitis C Virus in Moroccan Patients. **PLoS One**. 2013 January 14; 8(1): e54793.
188. Lemoine M, Girard PM, **Thursz M**, Raguin G. In the shadow of HIV/AIDS: Forgotten diseases in sub-Saharan Africa. Global health issues and funding agency responsibilities. *J Public Health Policy*. 2012 Aug 16. 33(4):430-8.
189. **Thursz M**, Njie R, Lemoine M. Hepatitis: Global eradication of hepatitis B-feasible or fallacy? *Nat Rev Gastroenterology Hepatology*. 2012 Sep;9(9):492-4.
190. Rashid ST, Humphries JD, Byron A, Dhar A, Askari JA, Selley JN, Knight D, Goldin RD, **Thursz M**, Humphries MJ. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. **Journal of Proteome Research**. 2012 Aug 3;11(8):4052-64.
191. Cobbold JF, Cox IJ, Brown AS, Williams HR, Goldin RD, Thomas HC, **Thursz MR**, Taylor-Robinson SD. Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. **Hepatology Research**. 2012 Jul;42(7):714-20.
192. European Association for the Study of Liver. EASL clinical practice guidelines: management of alcoholic liver disease. **Journal of Hepatology**. 2012 Aug;57(2):399-420
193. Levene AP, Kudo H, Armstrong MJ, **Thursz MR**, Gedroyc WM, Anstee QM, Goldin RD. Quantifying hepatic steatosis - more than meets the eye. **Histopathology**. 2012 May;60(6):971-81.
194. Raza M, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, **Thursz M**. The Role of Liver Fibrosis Assessment in the Management of Patients with Chronic Hepatitis B Infection: Lessons Learned from a Single Centre Experience. **Hepatitis Research and Treatment**. 2011 Oct 30; 2011: 524027.
195. Antoniadou CG, Quaglia A, Taams LS, Mity RR, Hussain M, Abeles R, Possamai LA, Bruce M, McPhail M, Starling C, Wagner B, Barnardo A, Pomplun S, Auzinger G, Bernal W, Heaton N, Vergani D, **Thursz MR**, Wendon J. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. **Hepatology**. 2012 Aug;56(2):735-46.

196. **Thursz M.** Get active. **Journal of Hepatology.** 2012 Jan;56(1):5-6.
197. Sauvage VR, Levene AP, Nguyen HT, Wood TC, Kudo H, Concas D, Thomas HC, **Thursz MR,** Goldin RD, Anstee QM, Elson DS. Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. **Laser in Surgery and Medicine.** 2011 Jul;43(5):392-400.
198. Sangwaiya A, Manglam V, Bubsbridge M, **Thursz M,** Arnold J. Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis. **European Journal of Gastroenterology & Hepatology.** 2011 Jun 4, 23(8)721-4
199. Anstee QM, Dhar A, **Thursz MR.** The role of hypercoagulability in liver fibrogenesis. **Clinics and Research in Hepatology and Gastroenterology.** 2011 May 12.
200. **Thursz M,** Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. **Seminars in Liver Diseases.** 2011 May;31(2):115-27.
201. **Thursz M,** Brown A. Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma? **Gut.** 2011 Apr 20.
202. Knapp S, Warshow U, Ho KM, Hegazy D, Little AM, Fowell A, Alexander G, **Thursz M,** Cramp M, Khakoo SI. A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals from Spontaneous Resolvers of HCV Infection. **Gastroenterology.** 2011 Apr 14.
203. Wadsworth CA, Ziprin P, Pelling MX, Jiao LR, **Thursz MR.** A case of HGV-related epigastric pain. Pancreatic fracture. **Gut.**2011 Feb;60(2):197, 284.
204. Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, **Thursz M,** Lim SG, Ocamo P, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. **Liver International.** 2010 Nov 28.
205. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, **Thursz MR,** Goldin RD. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. **Journal of Hepatology.**v2010 Sep;53(3):542-50.
206. Arnold J, Sangwaiya A, Manglam V, **Thursz M,** Beaumont C, Kannengiesser C, Busbridge M. Hecpidin levels in hereditary hyperferritinemia: Insights into the iron-sensing mechanism in hepatocytes. **World Journal of Gastroenterology.** 2010 Jul 28;16(28):3541-5.
207. Arnold J, Sangwaiya A, Manglam V, Geoghegan F, **Thursz M,** Busbridge M. Presence of hepcidin-25 in biological fluids: bile, ascitic and pleural fluids. **World Journal of Gastroenterology.** 2010 May 7;16(17):2129-33.
208. Levene AP, Kudo H, **Thursz MR,** Anstee QM, Goldin RD. Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver? **Hepatology.** 2010 May;51(5):1859.
209. Possamai LA, Antoniadis CG, Anstee QM, Quaglia A, Vergani D, **Thursz M,** Wendon J. Role of monocytes and macrophages in experimental and human acute liver failure. **World Journal of Gastroenterology.** 2010 Apr 21;16(15):1811-9.
210. Tanwar S, **Thursz M.** Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. **World Journal of Hepatology.**2010 Mar 27;2(3):136-8.
211. Khamri W, Walker MM, Clark P, Atherton JC, **Thursz MR,** Bamford KB, Lechler RI, Lombardi G. Helicobacter pylori stimulates dendritic cells to induce interleukin-17 expression from CD4+ T lymphocytes. **Infection and Immunity.** 2010 Feb;78(2):845-53.
212. Cooke GS, Main J, **Thursz MR.** Treatment for hepatitis B. **British Medical Journal.** 2010 Jan 5;340:b5429.

213. **Thursz M**, Cooke GS, Hall AJ. Hepatitis B treatment in resource poor settings: time for action. **Tropical Medicine & International Health**. 2010 Jan;15(1):2-4.
214. Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, **Thursz M**, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. **Vaccine**. 2009 Aug 13;27(37):5142-51.
215. Epstein D, Bojke L, Sculpher MJ; REFLUX trial group. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. *British Medical Journal*. 2009 Jul 14;339:b2576.
216. Cobbold JF, Anstee QM, Goldin RD, Williams HR, Matthews HC, North BV, Absalom N, Thomas HC, **Thursz MR**, Cox RD, Taylor-Robinson SD, Cox IJ. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. *Clin Sci (Lond)*. 2009 Mar;116(5):403-13.
217. Anstee QM, Wright M, Goldin R, **Thursz MR**. Parenchymal extinction: coagulation and hepatic fibrogenesis. **Clinics in Liver Disease**. 2009 Feb;13(1):117-26.
218. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, **Thursz MR**, Campbell MK; REFLUX Trial Group. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. **British Medical Journal**. 2008 Dec 15;337:a2664.
219. Calvaruso V, Maimone S, Gatt A, Tuddenham E, **Thursz M**, Pinzani M, Burroughs AK. Coagulation and fibrosis in chronic liver disease. **Gut**. 2008 Dec;57(12):1722-7.
220. Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, **Thursz M**, Russell I, Campbell M; REFLUX Trial Group. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX Trial. **Health Technology Assessment**. 2008 Sep;12(31):1-181, iii-iv.
221. Martinelli A, Knapp S, Anstee Q, Worku M, Tommasi A, Zucoloto S, Goldin R, **Thursz M**. Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. **Journal of Gastroenterology & Hepatology**. 2008 Sep;23(9):1403-9.
222. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, **Thursz MR**. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. **Journal of Thrombosis and Haemostasis**. 2008 Aug;6(8):1336-43.
223. Kennedy PT, Lee HC, Jeyalingam L, Malik R, Karayiannis P, Muir D, Main J, **Thursz M**, Goldin R, Smith B, Brown A, Thomas HC. NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years' experience in west London. **Antiviral Therapy**. 2008;13(8):1067-76.
224. Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, Zhang L, Thomas HC, **Thursz M**, Hill AV. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. **Liver International**. 2007 Oct;27(8):1134-43.
225. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, **Thursz M**, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C; HENCORE Group. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. **Journal of Viral Hepatitis**. 2007 Aug;14(8):556-63.
226. Anderson AE, Worku ML, Khamri W, Bamford KB, Walker MM, **Thursz MR**. TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. **European Journal of Immunology**. 2007 Jun;37(6):1548-61.

227. **Thursz M.** Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. **Gut.** 2007 May;56(5):613-4.
228. Khamri W, Worku ML, Anderson AE, Walker MM, Hawgood S, Reid KB, Clark HW, **Thursz MR.** Helicobacter infection in the surfactant protein D-deficient mouse. **Helicobacter.** 2007 Apr;12(2):112-23.
229. Tillmann HL, **Thursz M.** Hepatitis C virus infection--its role in pathogenesis. **Journal of Infectious Diseases.** 2007 Jan 15;195(2):168-70.
230. Dawes R, Hennig B, Irving W, Petrova S, Boxall S, Ward V, Wallace D, Macallan DC, **Thursz M,** Hill A, Bodmer W, Beverley PC, Tchilian EZ. Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. **Journal of Medical Genetics.** 2006 Aug;43(8):678-84.
231. Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, Hennig BJ, Hellier S, Knapp S, Wright M, Chiaramonte M, Bell JI, Graves M, Whittle HC, Thomas HC, **Thursz MR,** Hill AV. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. **Proc Natl Acad Sci USA.** 2006 Jun 13;103(24):9148-53.
232. Khamri W, Moran AP, Worku ML, Karim QN, Walker MM, Annuk H, Ferris JA, Appelmeik BJ, Eggleton P, Reid KB, **Thursz MR.** Variations in Helicobacter pylori lipopolysaccharide to evade the innate immune component surfactant protein D. **Infection and Immunity.** 2005 Nov;73(11):7677-86.
233. Rashid ST, **Thursz MR,** Razvi NA, Voller R, Orchard T, Rashid ST, Shlebak AA. Venous thromboprophylaxis in UK medical inpatients. **Journal of Royal Society of Medicine.** 2005 Nov;98(11):507-12.
234. Lin X, Robinson NJ, **Thursz M,** Rosenberg DM, Weild A, Pimenta JM, Hall AJ. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. **Journal of Gastroenterology & Hepatology.** 2005 Jun;20(6):833-43.
235. Moran AP, Khamri W, Walker MM, **Thursz MR.** Role of surfactant protein D (SP-D) in innate immunity in the gastric mucosa: evidence of interaction with Helicobacter pylori lipopolysaccharide. **Journal of Endotoxin Research.** 2005;11(6):357-62.
236. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, Grant P, **Thursz M,** Naoumov N, Millson C, Mills PR, Bassendine M, Thomas HC; UK Mild HCV Trial investigators. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. **Journal of Viral Hepatitis.** 2005 Jan;12(1):58-66.
237. Dave U, Taylor-Robinson SD, Walker MM, Mahon M, Puri BK, **Thursz MR,** DeSouza NM, Cox IJ. In vitro 1H-magnetic resonance spectroscopy of Barrett's esophageal mucosa using magic angle spinning techniques. **European Journal of Gastroenterology & Hepatology.** 2004 Nov;16(11):1199-205.
238. Luik A, Knapp S, **Thursz M,** Thomas HC, Schlaak JF. Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. **Journal of Interferon & Cytokine Research.** 2004 Oct;24(10):585-93.
239. Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, Chiaramonte M, Braconier JH, Hall AJ, **Thursz MR.** Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. **Journal of Viral Hepatitis.** 2004 Sep;11(5):459-64
240. **Thursz M.** Pros and cons of genetic association studies in hepatitis B. **Hepatology.** 2004 Aug;40(2):284-6.
241. Yee LJ, Knapp S, Burgner D, Hennig BJ, Frodsham AJ, Wright M, Thomas HC, Hill AV, **Thursz MR.** Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection. **Genes and Immunity.** 2004 May;5(3):183-7.

242. **Thursz M**, Moore K. Clinical management. Where medicine meets management. Can of worms. **Health Service Journal**. 2004 Mar 4;114(5895):28-9.
243. Dave U, **Thursz MR**, Ebrahim HY, Burke MM, Townsend ER, Walker MM. Distribution of laminins in the basement membranes of the upper gastrointestinal tract and Barrett's oesophagus. **Journal of Pathology**. 2004 Mar;202(3):299-304.
244. Dave UR, Williams AD, Wilson JA, Amin Z, Gilderdale DJ, Larkman DJ, **Thursz MR**, Taylor-Robinson SD, deSouza NM. Esophageal cancer staging with endoscopic MR imaging: pilot study. **Radiology**. 2004 Jan;230(1):281-6.
245. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC, **Thursz M**, Hill AV. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. **Hepatology**. 2003 Dec;38(6):1468-76.
246. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiamonte M, Graves M, Thomas HC, Hill AV, **Thursz MR**. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. **Genes and Immunity**. 2003 Sep;4(6):411-9.
247. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AV, Thomas HC, **Thursz MR**. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. **Immunogenetics**. 2003 Sep;55(6):362-9.
248. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, **Thursz M**. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. **Gut**. 2003 Aug;52(8):1206-10.
249. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, **Thursz M**. HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. **Gut**. 2003 Apr;52(4):574-9.
250. Wright M, **Thursz M**, Pullen R, Thomas H, Goldin R. Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. **Liver International**. 2003 Feb;23(1):28-34.
251. Forton DM, Wright M, Knapp S, **Thursz MR**, Taylor-Robinson SD, Thomas HC. New insights into hepatitis **Clinical Medicine Journal**. 2002 Nov-Dec;2(6):554-9.
252. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, **Thursz MR**, Wasan H; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. **Gut**. 2002 Nov;51
253. Hennig BJ, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S, Wright M, Thomas HC, **Thursz M**, Hill AV. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. **Genes Immun**. 2002 Sep;3(6):359-67
254. Walker MM, Worku M, Coggle S, **Thursz MR**. A novel method for assessing gastritis in the murine model demonstrates genetically determined variation in response to *Helicobacter felis* infection. **Helicobacter**. 2002 Aug;7(4):265-8.
255. Murray E, Khamri W, Walker MM, Eggleton P, Moran AP, Ferris JA, Knapp S, Karim QN, Worku M, Strong P, Reid KB, **Thursz MR**. Expression of surfactant protein D in the human gastric mucosa and during *Helicobacter pylori* infection. **Infection and Immunity**. 2002 Mar;70(3):1481-7.
256. Zampino R, Lobello S, Chiamonte M, Venturi-Pasini C, Dumpis U, **Thursz M**, Karayiannis P. Intra-familial transmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino-acid variation of the core gene. **Journal of Hepatology**. 2002 Feb;36(2):248-53.

257. Dumpis U, Mendy M, Hill A, **Thursz M**, Hall A, Whittle H, Karayiannis P. Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. **Journal of Medical Virology**. 2001 Dec;65(4):664-70.
258. **Thursz M**. Genetic susceptibility in chronic viral hepatitis. **Antiviral Research**. 2001 Nov;52(2):113-6.
259. Dumpis U, Holmes EC, Mendy M, Hill A, **Thursz M**, Hall A, Whittle H, Karayiannis P. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. **Journal of Hepatology**. 2001 Jul;35(1):99-104.
260. **Thursz M**. MHC and the viral hepatitis. **Quarterly Journal of Medicine**. 2001 Jun;94(6):287-91.
261. Godkin A, Jeanguet N, **Thursz M**, Openshaw P, Thomas H. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. **European Journal of Immunology**. 2001 May;31(5):1438-46.
262. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola RC, Sauleda S, **Thursz MR**, Tillmann H, Alberti A, Braconier JH, Esteban JI, Hadziyannis SJ, Manns MP, Saracco G, Thomas HC, Trépo C. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. **European Journal of Gastroenterology & Hepatology**. 2000 Jun;12(6):667-78.
263. Pradat P, Chossegros P, Bailly F, Pontisso P, Saracco G, Sauleda S, **Thursz M**, Tillmann H, Vlassopoulou H, Alberti A, Braconier JH, Esteban JI, Hadziyannis S, Manns M, Rizzetto M, Thomas HC, Trépo C. Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. **Journal of Viral Hepatitis**. 2000 May;7(3):203-10.
264. **Thursz M**. Genetic susceptibility in infectious diseases. **Biotechnology & Genetic Engineering Reviews**. 2000;17:253-64.
265. **Thursz M**, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. **Lancet**. 1999 Dec 18-25;354(9196):2119-24.
266. Bellamy R, Ruwende C, Corrah T, McAdam KP, **Thursz M**, Whittle HC, Hill AV. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. **Journal of Infectious Diseases**. 1999 Mar;179(3):721-4
267. Ojo OS, Akonai AK, **Thursz M**, Ndububa DA, Durosinmi MA, Adeodu OO, Fatusi OA, Goldin RD. Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. **East African Medical Journal**. 1998 Jun;75(6):329-31.
268. Bellamy R, Ruwende C, McAdam KP, **Thursz M**, Sumiya M, Summerfield J, Gilbert SC, Corrah T, Kwiatkowski D, Whittle HC, Hill AV. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. **Quarterly Journal of Medicine**. 1998 Jan;91(1):13-8.
269. **Thursz MR**, Thomas HC, Greenwood BM, Hill AV. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. **Nature Genetics**. 1997 Sep;17(1):11-2.
270. **Thursz MR**. Host genetic factors influencing the outcome of hepatitis. **Journal of Viral Hepatitis**. 1997 Jul;4(4):215-20.

271. Shanmuganathan S, Waters JA, Karayiannis P, **Thursz M**, Thomas HC. Mapping of the cellular immune responses to woodchuck hepatitis core antigen epitopes in chronically infected woodchucks. **Journal of Medical Virology**. 1997 Jun;52(2):128-35.
272. Carman WF, Boner W, Fattovich G, Colman K, Dornan ES, **Thursz M**, Hadziyannis S. Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. **Journal of Infectious Diseases**. 1997 May;175(5):1093-100.
273. Thomas HC, **Thursz MR**. Immunogenetics of hepatitis B virus infection. **Journal of Viral Hepatitis**. 1997;4 Suppl 2:98-100.
274. **Thursz MR**, Thomas HC. Host factors in chronic viral hepatitis. **Seminars in Liver Diseases**. 1997;17(4):345-50.
275. Karayiannis P, Alexopoulou A, Hadziyannis S, **Thursz M**, Watts R, Seito S, Thomas HC. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. **Hepatology**. 1995 Dec;22(6):1628-34.
276. Ojo OS, **Thursz M**, Thomas HC, Ndububa DA, Adeodu OO, Rotimi O, Lawal AA, Durosinmi MA, Akonai AK, Fatusi AO, et al. Hepatitis B virus markers, hepatitis D virus antigen and hepatitis C virus antibodies in Nigerian patients with chronic liver disease. **East African Medical Journal**. 1995 Nov;72(11):719-21.
277. Fattovich G, McIntyre G, **Thursz M**, Colman K, Giuliano G, Alberti A, Thomas HC, Carman WF. Hepatitis B virus precore/core variation and interferon therapy. **Hepatology**. 1995 Nov;22(5):1355-62.
278. Gewert DR, Sharp NA, Barber KA, Cooper H, Tucker D, Lewis AP, **Thursz M**, Crowe JS. Detection of rare allelic variants of the interferon-alpha 2 gene in human genomic DNA. **Journal of Interferon & Cytokine Research**. 1995 May;15(5):403-6.
279. **Thursz MR**, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. **The New England Journal of Medicine**. 1995 Apr 20;332(16):1065-9.
280. Summerfield JA, Ryder S, Sumiya M, **Thursz M**, Gorchein A, Monteil MA, Turner MW. Mannose binding protein gene mutations associated with unusual and severe infections in adults. **Lancet**. 1995 Apr 8;345(8954):886-9.
281. **Thursz MR**, Kwiatkowski D, Torok ME, Allsopp CE, Greenwood BM, Whittle HC, Thomas HC, Hill AV. Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. **Nature Medicine**. 1995 Apr;1(4):374-5.
282. Carman WF, **Thursz M**, Hadziyannis S, McIntyre G, Colman K, Gioustoz A, Fattovich G, Alberti A, Thomas HC. Hepatitis B e antigen negative chronic active hepatitis: hepatitis B virus core mutations occur predominantly in known antigenic determinants. **Journal of Viral Hepatitis**. 1995;2(2):77-84.
283. Crowe JS, Gewert DR, Barber KA, Lewis AP, Sims MJ, Davies SL, Salom CL, Wood J, Thomas HC, **Thursz M**, et al. Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy. **Journal of Infectious Diseases**. 1994 Apr;169(4):875-8.
284. Hunt JB, Appleyard M, **Thursz M**, Carey PD, Guillou PJ, Thomas HC. Intraoperative haemorrhage from anterior abdominal wall varices. *Postgraduate Medical Journal*. 1993 Jun;69(812):490-3.

Books & Chapters

1. Host surfactant proteins in microbial recognition. Khamri W. Thursz MR in *Microbial Glycobiology*. Moran A ed. Cambridge 2008.
2. Hepatitis B and C. Yee L. Thursz M. in *Genetics of Infectious Disease*. Kaslow R, Hill AVS eds OUP 2007

3. Pathogenesis of Hepatitis B Virus Infection. Thursz MR, Thomas HC. Viral Hepatitis. (3rd edition) Zuckerman AJ & Thomas HC eds. Churchill Livingstone, Edinburgh, 2004.
4. Walker M, Thursz M, Teare J, Warren B. "Practical Endoscopic Pathology: Upper Gastrointestinal Tract: Ulcers and Inflammation" (Blackwell Sci Inc. Oxford) 2000
5. Hepatitis B virus infection and immunity. Waters,J.A. Foster,G.R. Thursz,M.R. and Thomas,H.C. Human Tumour Viruses. McCance,D.J. ed. ASM Press, Washington DC 1998.
6. Future Therapies for B Virus Chronic Hepatitis. Thursz M, Thomas HC. Progress in Hepatology 93. JP Miguet and D Dhumeaux, eds. John Libbey Eurotext, Paris. 1993.
7. Pathogenesis of Hepatitis B Virus Infection. Thursz MR, Thomas HC. Viral Hepatitis. (2nd edition) Zuckerman AJ & Thomas HC eds. Churchill Livingstone, Edinburgh, 1997.